Assessing Treatment Benefit in Immuno-oncology

Marc Buyse (), Everardo D. Saad, Tomasz Burzykowski and Julien Péron
Additional contact information
Marc Buyse: International Drug Development Institute
Everardo D. Saad: International Drug Development Institute
Tomasz Burzykowski: Hasselt University
Julien Péron: Hospices Civils de Lyon

Statistics in Biosciences, 2020, vol. 12, issue 2, No 2, 83-103

Abstract: Abstract Immuno-oncology is a buoyant field of research, with recently developed drugs showing unprecedented response rates and/or a hope for a meaningful prolongation of the overall survival of some patients. These promising clinical developments have also pointed to the need of adapting statistical methods to best describe and test for treatment effects in randomized clinical trials. We review adaptations to tumor response and progression criteria for immune therapies. Survival may be the endpoint of choice for clinical trials in some tumor types, and the search for surrogate endpoints is likely to continue to try and reduce the duration and size of clinical trials. In situations for which hazards are likely to be non-proportional, weighted logrank tests may be preferred as they have substantially more power to detect late separation of survival curves. Alternatively, there is currently much interest in accelerated failure time models, and in capturing treatment effect by the difference in restricted mean survival times between randomized groups. Finally, generalized pairwise comparisons offer much promise in the field of immuno-oncology, both to detect late emerging treatment effects and as a general approach to personalize treatment choices through a benefit/risk approach.

Keywords: Immuno-oncology; Immune RECIST; Weighted logrank test; Accelerated failure time model; Restricted mean survival time; Generalized pairwise comparisons (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s12561-020-09268-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:stabio:v:12:y:2020:i:2:d:10.1007_s12561-020-09268-1

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/12561

DOI: 10.1007/s12561-020-09268-1

Access Statistics for this article

Statistics in Biosciences is currently edited by Hongyu Zhao and Xihong Lin

More articles in Statistics in Biosciences from Springer, International Chinese Statistical Association
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().